[Good News]

CytoNiche Co., Ltd., (hereafter referred to as "CytoNiche") has been approved to build a park-type postdoctoral research station, according to a notice from Beijing Human Resources and Social Security Bureau.

The establishment of this postdoctoral research station can make full use of the advantages of the postdoctoral system in scientific and technological research and management mechanisms, gradually form a mechanism for cooperation between enterprises, universities, and research institutes, etc. Eventually, higher education institutions and research institutes will be promoted to link with enterprises, and the industry-university-research combination will be further enhanced to make enterprises more competitive and stronger in technological innovation.

The award represents the government's strong affirmation of CytoNiche's work in scientific and technological innovation, talent training, and the transformation of research achievements. This is a significant milestone in our efforts to build a world-class team of scientific and technological leaders and innovators.

Founded in August 2018, CytoNiche has been recognized as a Zhongguancun High-tech Enterprise and National High-tech Enterprise in turn, and gets financial support from the Disruptive Technology Research and Development and Achievement Transformation Project of Zhongguancun Science and Technology Park.

As an excellent research and innovation enterprise, CytoNiche understands the importance of talents, and has gathered a group of top scientists in the field of biomedicine from Tsinghua University, Peking University, Chinese Academy of Sciences and other domestic top universities and research institutes, thus forming the core R&D team of CytoNiche. CytoNiche employees have published more than one hundred papers in domestic and international core journals, and have received over one hundred patents in the biomedicine field. Simultaneously, CytoNiche has put various technologies into production and transformed them into eye-catching products and services that strongly promote the development of the biotechnology field.

The establishment of the postdoctoral research workstation will pave the way for CytoNiche to sign strategic cooperation agreements with Tsinghua University and other higher research institutions to jointly train postdoctoral researchers by virtue of the advantages of CytoNiche's core technological talents team. With the support of the postdoctoral workstation, CytoNiche will make a significant advancement in forging a talent team and scientific research platform, increase the channels for introducing high-level talents, and establish a virtuous cycle of accumulating, cultivating, and retaining talents.

Simultaneously, the management mechanism for postdoctoral researchers will encourage innovations in training and utilization of talents, and spread the innovations to break through the constraints of the current hiring and distribution system. Each postdoctoral talent that joins the high-level talent cluster of CytoNiche will play a significant role in boosting scientific research, innovation, and talents development.

[CytoNiche: Kicking off a New Era in Cellular Industrialization]

CytoNiche will enhance its industrial demonstration role and leadership position to promote the building and operation management of postdoctoral research workstations on a continuous basis. The combination of introduction and training produces the highest quality scientific research and transformation platform for outstanding scientific and technological innovation talents capable of conducting original research and converting technologies. The focuses on technology development and implementation of 3D cellular intelligence and regenerative medicine in the field of biomedicine, the promotion of the deep integration of cellular industry and its derivatives with social development, and the enhancement of the innovation power of Beijing's pharmaceutical industry, are beneficial for improving people's health and well-being, and ushering in a new era of cellular industrialization development.

【CytoNiche】

Beijing CytoNiche Biotechnology Co., Ltd. was established by the research team of Professor Du Yanan from Tsinghua University School of Medicine, and was jointly established by Tsinghua University through equity participation. The core technologies were derived from the transformation of scientific and technological achievements of Tsinghua University. CytoNiche focuses on building an original 3D cell "smart manufacturing" platform, as well as providing overall solutions for the 3D microcarrier-based customized cell amplification process.

CytoNiche's core product, 3D TableTrix® Microcarrier Tablet (Microcarrier), is an independent innovation and the first pharmaceutical excipient grade microcarrier that can be used for cell drug development. It has obtained the certificate of analysis from relevant authoritative institutions such as National Institutes for Food and Drug Control, and obtained 2 qualifications for pharmaceutical excipients from the National Medical Products Administration (CDE approval registration number: F20210000003, F20200000496). Moreover, the product has obtained the DMF qualification for pharmaceutical excipients from U.S. FDA (DMF: 35481). 

Products and services of CytoNiche can be widely used in the upstream process development of gene and cell therapy, extracellular vesicles, vaccines, and protein products. At the same time, it also has broad prospects for applications in the fields of regenerative medicine, organoids, and food technology (cell-cultured meat, etc.).

Our company has a R&D and transformation platform of 5,000 square meters, including a CDMO platform of more than 1,000 square meters, a GMP production platform of 4,000 square meters, and a new 1200 L microcarrier production line. The relevant technologies have obtained more than 100 patents and more than 30 articles about the technologies in international journals have been published. The core technology projects have obtained a number of national-level project support and applications.